Immune checkpoint inhibitor-related cutaneous adverse events

被引：8
|
作者：
He, Chunxia [1 ]
Qu, Tao [1 ]
机构：
[1] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Natl Clin Res Ctr Skin & Immune Dis, Dept Dermatol, 1 Shuai Fu Yuan, Beijing 100730, Peoples R China
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 16卷 / 05期
关键词：
cutaneous toxicities; immune checkpoint inhibitors; immune-related adverse events; outcomes; rechallenge; ASSOCIATION; PEMBROLIZUMAB; IMMUNOTHERAPY; MANAGEMENT; IPILIMUMAB; NIVOLUMAB; VITILIGO;
D O I：
10.1111/ajco.13364
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Cutaneous toxicities are the most prevalent immune-related adverse events. Various reactions have been reported. In this review, we summarized the clinicopathologic manifestations, treatment strategies, relevance to tumor outcomes, and rechallenge considerations of cutaneous immune-related adverse events.
引用
收藏
页码：E149 / E153
页数：5
相关论文
共 50 条
  • [1] Rheumatologic immune checkpoint inhibitor-related adverse events
    Defoe, Melissa
    Bermas, Bonnie L.
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2023, 35 (03) : 141 - 148
  • [2] Immune checkpoint inhibitor-related dermatologic adverse events
    Geisler, Amaris N.
    Phillips, Gregory S.
    Barrios, Dulce M.
    Wu, Jennifer
    Leung, Donald Y. M.
    Moy, Andrea P.
    Kern, Jeffrey A.
    Lacouture, Mario E.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (05) : 1255 - 1268
  • [3] Management of immune checkpoint inhibitor-related dermatologic adverse events
    Si, Xiaoyan
    He, Chunxia
    Zhang, Li
    Liu, Xiaowei
    Li, Yue
    Wang, Hanping
    Guo, Xiaoxiao
    Zhou, Jiaxin
    Duan, Lian
    Wang, Mengzhao
    [J]. THORACIC CANCER, 2020, 11 (02) : 488 - 492
  • [4] Management of immune checkpoint inhibitor-related rheumatic adverse events
    Zhou, Jiaxin
    Wang, Hanping
    Guo, Xiaoxiao
    Wang, Qian
    Duan, Lian
    Si, Xiaoyan
    Zhang, Li
    Liu, Xiaowei
    Li, Yue
    Zhang, Wen
    [J]. THORACIC CANCER, 2020, 11 (01) : 198 - 202
  • [5] Reply to "Immune checkpoint inhibitor-related dermatologic adverse events''
    Stephan, Carla
    Khalil, Joanna
    Abbas, Ossama
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (06) : E297 - E298
  • [6] Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
    Poto, Remo
    Troiani, Teresa
    Criscuolo, Gjada
    Marone, Giancarlo
    Ciardiello, Fortunato
    Tocchetti, Carlo Gabriele
    Varricchi, Gilda
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [7] Immune checkpoint inhibitor-related luminal GI adverse events
    Kroner, Paul T.
    Mody, Kabir
    Farraye, Francis A.
    [J]. GASTROINTESTINAL ENDOSCOPY, 2019, 90 (06) : 881 - 892
  • [8] Limitations of morphology-based management for immune checkpoint inhibitor-related cutaneous adverse events
    Otto, Tracey S.
    Chang, Michael S.
    Thompson, Leah L.
    Chen, Steven T.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (06) : E281 - E282
  • [9] Mechanisms and Management of Immune Checkpoint Inhibitor-Related Cardiac Adverse Events
    Kadowaki, Hiroshi
    Akazawa, Hiroshi
    Ishida, Junichi
    Komuro, Issei
    [J]. JMA JOURNAL, 2021, 4 (02): : 91 - 98
  • [10] Landscape of immune checkpoint inhibitor-related adverse events in Chinese population
    Li, Li
    Li, Gang
    Rao, Bin
    Dong, An-Hui
    Liang, Wei
    Zhu, Jin-Xian
    Qin, Mu-Ping
    Huang, Wen-Wen
    Lu, Jie-Ming
    Li, Zi-Fang
    Wu, Yao-Zhong
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
12345